AroCell on ProHearings In Stockholm
Now on Friday, February 16, participating AroCell on ProHearings in Stockholm.
AroCell will be presented there is a 8.40 Jan Stålemark, CEO.
The presentation will be broadcasted live on this link: https://www.youtube.com/watch?v=TlnG8E33DlY .
The entire program for the day is available here: http://www.prohearings.com/ .
If you want to participate register for the Info@prohearings.com
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the treatment, prognosis, and follow-up of cancer patients. AroCells technology is based on patented methods for measuring the protein Thymidine Kinase 1 (then the tk1) in a blood sample. TK 210(TM) ELISA test provides valuable information that can help clinicians to optimize treatment strategies and to forecast the risk of recurrence of cancer at the monitoring and follow-up of the patient. AroCell (AROC) is listed on Nasdaq First North with Redeye AB as Certified Adviser.
For more information, see www.arocell.com.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire